Study Design and Rationale for the Phase 3 Clinical Development Program of Enobosarm, a Selective Androgen Receptor Modulator, for the Prevention and Treatment of Muscle Wasting in Cancer Patients (POWER Trials)

Title
Study Design and Rationale for the Phase 3 Clinical Development Program of Enobosarm, a Selective Androgen Receptor Modulator, for the Prevention and Treatment of Muscle Wasting in Cancer Patients (POWER Trials)
Authors
Keywords
Muscle wasting, Sarcopenia, Selective androgen receptor modulator, Cachexia, Non-small-cell lung cancer, Enobosarm, Cachexia treatment, Cachexia therapy
Journal
Current Oncology Reports
Volume 18, Issue 6, Pages -
Publisher
Springer Nature
Online
2016-05-02
DOI
10.1007/s11912-016-0522-0

Ask authors/readers for more resources

Reprint

Contact the author

Add your recorded webinar

Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.

Upload Now

Create your own webinar

Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.

Create Now